A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD), according to results of a phase II ...
Key Points Interested in Opus Genetics, Inc.? Here are five stocks we like better. Opus Genetics highlighted a broad ...
Please provide your email address to receive an email when new articles are posted on . At Clinical Trials at the Summit, Abbey addressed concerns about using gene therapy in both eyes. However, in 11 ...
Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Lejla Vajzovic, MD, ...
Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.
MUNICH, Germany, April 10, 2024 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation clinical-stage gene therapy company, today announced that the first patient has been dosed in its Phase Ib ...
Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and regulatory steps clustered into 2026 and early 2027. The s ...
Shares of the gene therapy developer rose 12.5% to $9.55 in premarket trading on Monday after the news. Sign up here. Under the deal, MeiraGTx will get an upfront payment of $75 million and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results